about
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialGreater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion.Palliative treatment of malignant ascites: profile of catumaxomab.Malignant ascites: pathophysiology and treatment.Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascitesAnti-tumoral effects of a trypsin inhibitor derived from buckwheat in vitro and in vivo.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheterManagement of non-ovarian cancer malignant ascites through indwelling catheter drainage.PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success.A pilot study of long-acting octreotide for symptomatic malignant ascites.Paracentesis in the management of ascites.Supportive care for women with gynecologic cancers.Treatment of malignant ascites.An automated spring-loaded needle for endoscopic ultrasound-guided abdominal paracentesis in cancer patients.Repositioning of surgically placed peritoneovenous shunt catheter by forming "in situ" loop snare: case report and review of literature.Catumaxomab: in malignant ascites.The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature.Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.Targeted removal of migratory tumor cells by functionalized magnetic nanoparticles impedes metastasis and tumor progression.Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis.Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.Symptomatic Fluid Drainage: Tunneled Peritoneal and Pleural Catheters.Nanoformulations of albendazole as effective anticancer and antiparasite agents.Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.A survey of treatment approaches of malignant ascites in Germany and Austria.Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites.Polysaccharides Extracted from Rhizoma Pleionis Have Antitumor Properties In Vitro and in an H22 Mouse Hepatoma Ascites Model In Vivo.Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model.Recruitment and significance of Th22 cells and Th17 cells in malignant ascites
P2860
Q24629295-81D476D6-D12A-4C6F-9967-3292E2B72C7EQ33798812-3E66CBEE-0E29-420A-8B14-797A399EF508Q33892606-D7EDADFB-E45F-435E-AE3B-D1EAA0AC141DQ34213359-0DCF6A3F-F877-4558-B36C-59A3DD1950E8Q35168699-D674FFF0-34F2-47D8-898B-E6BA432E7E21Q35728911-44CFDA53-6C26-4B2E-9A8F-8C81BCAFD2B9Q35758912-9A2CD837-B834-4B0D-AC73-E2CAE373891FQ35957129-CD4A588C-3896-4202-8584-DDC4B8ECBA08Q35994293-B0B836B6-4250-43E6-8E3E-AE8BDCB8652BQ35996680-0BD991FA-0A50-4A56-9C19-5C88F83554E9Q36343907-C40EF6CE-FA63-4C34-876F-F9F6E862897FQ36573912-924931F4-2F66-49EC-9E6B-F5BC548F828BQ36977995-47AE6960-C0AC-43F8-ACCE-64AE65292810Q37086010-513784F5-6773-4E1F-8A48-7424F394340DQ37262873-E538A12A-8CB3-4522-9DE6-D2B6978BB85AQ37596005-8992BFA6-10CC-4AE0-BAE3-9263A6F0E4FFQ37966657-646A34E4-DA51-4CA0-97D7-B47BD2F93619Q38016957-9A9047D0-36BC-49F2-B6B6-937ADDA7C017Q38104263-F71F594F-DB9A-4009-BBB2-B46B5AB0DB54Q39171689-A0AFEAC9-1FBD-4C32-B717-1F416B61D129Q39616516-0D83BF02-BDB9-4D4C-BFF9-0C6A6E559BF8Q44230207-F2E28610-E25A-4128-A95F-B7F6F5B56DA1Q46118058-FE658513-096B-4D3E-85CA-7FF915BCBA5CQ47321790-49C7A1E7-AFB6-44FF-9709-7F150B8BF7F9Q47678586-56F53036-A8FA-4940-AF97-0583314F2341Q47867646-04C58D2C-BA9D-4677-BB84-1ED5F9E692C1Q48052474-EAA485E7-63BD-47ED-A7CA-7D52FBE554DCQ48055525-204BF6AB-F351-4C05-8D7C-B7831E8BBF01Q48073500-4E6C3E4C-9076-4F10-B297-0E72F5DEDF6BQ53686498-E235AD95-5192-42A0-9E1C-20B4B42B8588Q55396474-0121F46B-7BB8-421E-8D9A-A1A0D8950011Q58772549-7502A53E-267A-4A79-847D-019AE28534DB
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The current and future management of malignant ascites.
@ast
The current and future management of malignant ascites.
@en
type
label
The current and future management of malignant ascites.
@ast
The current and future management of malignant ascites.
@en
prefLabel
The current and future management of malignant ascites.
@ast
The current and future management of malignant ascites.
@en
P356
P1433
P1476
The current and future management of malignant ascites.
@en
P2093
P356
10.1053/CLON.2002.0135
P577
2003-04-01T00:00:00Z